KIT and gastrointestinal stromal tumor: To date, there is no consistent and validated prognostic biomarker routinely used in patients with resected GIST other than mutation status in receptor tyrosine kinases (RTKs) KIT or PDGFRA, likely because of the lack of in-depth understanding in the biological mechanisms of disease relapse beyond kinase-activating mutations.